Subscribe to Seeking Alpha feed
https://seekingalpha.com
URL: https://seekingalpha.com
Updated: 43 min 33 sec ago

Arcellx a new overweight at Wells Fargo on promise of multiple myeloma CAR-T asset

Mon, 12/22/2025 - 17:16

2 Closed-End Funds For Utility Exposure With Monthly Distributions

Mon, 12/22/2025 - 17:15

Philips: Waiting Comfortably For Upside From Healthcare AI Leadership

Mon, 12/22/2025 - 17:06

Harbour Energy plc (HBRIY) Harbour Energy plc, - M&A Call - Slideshow

Mon, 12/22/2025 - 17:02

Norfolk Southern Corporation (NSC) Union Pacific Corporation - M&A Call - Slideshow

Mon, 12/22/2025 - 17:02

Colruyt Group N.V. 2026 Q2 - Results - Earnings Call Presentation

Mon, 12/22/2025 - 17:00

Harbor Small Cap Value Fund Q3 2025 Commentary

Mon, 12/22/2025 - 17:00

Trinity Capital: Beautiful Monthly Dividends, 13.5% Yield, My 2026 Income Pick

Mon, 12/22/2025 - 16:55

Becton, Dickinson accused of hindering competition in hernia mesh market

Mon, 12/22/2025 - 16:54

NexPoint Real Estate Finance: Attractive Valuation Heading Into 2026

Mon, 12/22/2025 - 16:47

Macquarie Value Fund Q3 2025 Commentary

Mon, 12/22/2025 - 16:45

Cytokinetics: Small Label Differences With Big Commercial Stakes

Mon, 12/22/2025 - 16:33

Target, Walmart added as defendants in ByHeart contaminated baby formula suits

Mon, 12/22/2025 - 16:28

Dollar General's High Valuation Means It's Time To Take Profits

Mon, 12/22/2025 - 16:21

Blue Owl Capital: When Private Credit Meets The AI Infrastructure Boom

Mon, 12/22/2025 - 16:19

Christmas Time On Wall Street

Mon, 12/22/2025 - 16:15

ZIM Integrated gains after update on strategic review process

Mon, 12/22/2025 - 16:15

Paranovus Entertainment Technology receives Nasdaq delisting notice

Mon, 12/22/2025 - 16:15

The AI Bubble Burst Phase One: Here's What's Coming Next

Mon, 12/22/2025 - 16:13

Neurocrine's Ingrezza fails in phase 3 trial for dyskinetic cerebral palsy

Mon, 12/22/2025 - 16:12

Pages